Eli Lilly and Company (NYSE: LLY) announced on Thursday that the U.S. Food and Drug Administration (FDA) had granted approval to Retevmo (selpercatinib, 40 mg & 80 mg capsules) for adult patients with locally advanced or metastatic solid tumors.
Retevmo can be used in the treatment of transfection (RET) gene fusion where a piece of DNA fuses with another gene in patients with tumors.
The FDA also granted approval to Retevmo for the treatment of RET gene fusion in non-small cell lung cancer (NSCLC) in adult patients.
David Hyman, M.D., chief medical officer, Loxo at Lilly commented, “Retevmo is the first and only RET inhibitor to receive both tumor-agnostic accelerated approval and traditional approval in NSCLC, further supporting its ability to deliver meaningful clinical benefit for patients across diverse tumor types.”
